[3H]Monoamine releasing and uptake inhibition properties of 3,4-methylenedioxymethamphetaimne and p-chloroamphetamine analogues

https://doi.org/10.1016/0014-2999(91)90659-EGet rights and content

Abstract

The ability of several 3,4-methylenedioxymethamphetamine (MDMA) analogues to inhibit the uptake of [3H]serotonin (5-HT), dopamine (DA) and norepinephrine (NE) into synaptosomes was examined. In addition, the ability of the compounds to inhibit the uptake of [3H]-HT and DA into synaptosomes from rats pretreated with reserpine (5 mg/kg i.p., 16 h pretreatment) was compared to control experiments. All of the test compounds were found to be potent releasers of non-vesicular 5-HT (the reserpine IC50 was significantly smaller than the control IC50). The range of 5-HT inhibitory activity corresponds well to the small range of ED50 values of the test compounds to substitute in drug discrimination experiments with animals trained to discriminate MDMA or S-(+)-N-methyl-1-(1,3-benzodioxol-5-yl)-2-aminobutane (S-MBDB) from saline. In contrast, there was a wide range of potency for the inhibition of NE and DA uptake. In addition, several of the analogues appeared to be pure uptake inhibitors of DA while others were found to be releasers of non-vesicular DA. Several of the compounds were very selective for 5-HT over DA or NE uptake inhibition, including 3-methoxy-4-methylamphetamine (MMA) and 5-methoxy-6-methyl-2-aminoindan (MMAI). A correlation was noted between the 5-HT neurotoxic potential of some of the test compounds and their relative ability to induce a release of non-vesicular DA. The potential catechol metabolites of the methylenedioxy-substituted compounds also showed potent monoamine releasing properties, suggesting that metabolism may play a role in the neurotoxic actions of some of these drugs. The present data support the hypothesis that drug-stimulated non-vesicular 5-HT release is primarily responsible for the discriminative cue of MDMA.

References (54)

  • G.M. Marquardt et al.

    Metabolism of β-3,4-methylenedioxyamphetamine in the rat

    Biochem. Pharmacol.

    (1978)
  • D.E. Nichols et al.

    5-Iodo-2-aminoindan: A non-neurotoxic analogue of p-doamphetamine

    Pharmacol. Biochem. Behav.

    (1991)
  • S.B. Ross

    Interactions between reserpine and various compounds on the accumulation of [14C]5-hydroxytryptamine and [3H]noradrenaline in homogenates from rat hypothalamus

    Biochem. Pharmacol.

    (1979)
  • C.J. Schmidt

    Acute administration of methylenedioxymethainphetamine: comparison with the neurochemical effects of its N-desmethyl and N-ethyl analogs

    European J. Pharmacol.

    (1987)
  • C.J. Schmidt et al.

    In vitro and in vivo neurochemical effects of methylenedioxymethamphetamine on stiatal monoaminergic systems in the rat brain

    Biochem. Pharmacol.

    (1987)
  • C.J. Schmidt et al.

    Depression of rat brain tryptophan hydroxylase activity following the acute administration of methylenedioxymethamphetamine

    Biochem. Pharmacol.

    (1987)
  • T.D. Steele et al.

    Stereochemica 1 effects of 3,4-methylenedioxymethamphetamine (MDMA) and related amphetamine derivatives on inhibition of uptake of [3H]monoamines into synaptosomes from different regions of rat brain

    Biochem. Pharmacol

    (1987)
  • D.M. Stone et al.

    A comparison of the neurotoxic potential of methylenedioxyam-phetamine (MDA) and its N-methylated and N-ethylated derivatives

    European J. Pharmacol.

    (1987)
  • D.M. Stone et al.

    The effects of 3,4-methylenedioxymethamphetamine (MDMA) and 3,4-methylenedioxyamphetamine (MDA) on monoaminergic systems in the rat brain

    European J. Pharmacol.

    (1986)
  • A.-L. Ask et al.

    Release of [3H]5-hydroxytryptamine by amiflamine and related phenylalkyi-amines from rat occipital cortex slices

    Naunyn-Schmiedeb. Arch. Pharmacol.

    (1989)
  • A.-L. Ask et al.

    Inhibition of 5-hydroxytryptaniine accumulation and deamination by substituted phenylalkylamines in hypothalamic synaptosomes from normal and reserpine-pretreated rats

    Naunyn-Schmiedeb. Arch. Pharmacol.

    (1987)
  • G. Battaglia et al.

    3,4-Methylenedioxymethamphetamine and 3,4-methylenedioxyamphetamine destroy serotonin terminals in rat brain: Quantification of neurodegeneration by measurement of [3H]paroxetine-labeled serotonin uptake sites

    J. Pharmacol. Exp.Ther.

    (1987)
  • C.W. Callaway et al.

    Serotonin release contributes to the locomotor stimulant effects of 3,4-methylene-dioxyrnethainphetamine (MDMA) in rats

    J. Pharmacol. Exp. Ther.

    (1990)
  • A.K. Cho et al.

    Stereochemical differences in the metabolism of 3,4-methylenedioxymethamphetamine in vivo and in vitro: A pharmacokinetic analysis

    Drug Metab. Disp.

    (1990)
  • D.L. Commins et al.

    Biochemical and histological evidence that methylenedioxymethamphetamine (MDMA) is toxic to neurons in the rat brain

    J. Pharmacol. Exp. Ther.

    (1987)
  • R.W. Fuller et al.

    6-Chloro-2-aminotetralin, a rigid confornialional analog of 4-chloroamphetamine: Pharmacological properties of it and related compounds in rats

    Arch., Int. Pharmacodyn.

    (1974)
  • R.W. Fuller et al.

    p-Iodoamphetamine as a serotonin depletor in rats

    J. Pharmacol. Exp. Ther.

    (1980)
  • Cited by (90)

    • Use of in vitro models in drug development and issue resolution

      2018, Advanced Issue Resolution in Safety Pharmacology
    • Pharmacological profiles of aminoindanes, piperazines, and pipradrol derivatives

      2014, Biochemical Pharmacology
      Citation Excerpt :

      Similar inhibitory effects of 5-IAI and MDAI on human monoamine transporters have recently been shown [7], but no comparable data on monoamine release are available. In contrast to the human transporter studies, both MDAI and 5-IAI were relatively more potent SERT and DAT vs. NET inhibitors in rat brain synaptosomes [33]. Similar to our data, MDAI released 5-HT, but not DA, and 5-IAI released both 5-HT and DA from rat brain synaptosomes [33].

    View all citing articles on Scopus
    View full text